menu
    • menu

    Find Angiotensin II manufacturers, exporters & distributors on PharmaCompass

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-20

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass

    Synopsis

    Related ProductsRelated Products

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    4

    API Suppliers

    API Suppliers

    3

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    KDMF

    KDMF

    1

    NDC API

    NDC API

    0

    VMF

    NDC API

    1

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 0

    MARKET PLACE

    0

    API

    0

    FDF

    0INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    3

    FDF Dossiers

    FDF Dossiers

    3

    FDA Orange Book

    FDA (Orange Book)

    0

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    3DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    8

    Others

    PATENTS & EXCLUSIVITIES

    45

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    5

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    NA

    Finished Drug Prices

    NA

    31 RELATED EXCIPIENT COMPANIES

    62EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: 4474-91-3, Angiotensin ii human, Hypertensin, Human angiotensin ii, Angiotensin ii (human), Ang ii
    Molecular Formula
    C50H71N13O12
    Molecular Weight
    1046.2  g/mol
    InChI Key
    CZGUSIXMZVURDU-JZXHSEFVSA-N
    Angiotensin II
    An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS.
    1 2D Structure

    Angiotensin II

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (3S)-3-amino-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[(2S)-2-[[(1S)-1-carboxy-2-phenylethyl]carbamoyl]pyrrolidin-1-yl]-3-(1H-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-oxobutanoic acid
    2.1.2 InChI
    InChI=1S/C50H71N13O12/c1-5-28(4)41(47(72)59-36(23-31-25-54-26-56-31)48(73)63-20-10-14-38(63)45(70)60-37(49(74)75)22-29-11-7-6-8-12-29)62-44(69)35(21-30-15-17-32(64)18-16-30)58-46(71)40(27(2)3)61-43(68)34(13-9-19-55-50(52)53)57-42(67)33(51)24-39(65)66/h6-8,11-12,15-18,25-28,33-38,40-41,64H,5,9-10,13-14,19-24,51H2,1-4H3,(H,54,56)(H,57,67)(H,58,71)(H,59,72)(H,60,70)(H,61,68)(H,62,69)(H,65,66)(H,74,75)(H4,52,53,55)/t28-,33-,34-,35-,36-,37-,38-,40-,41-/m0/s1
    2.1.3 InChI Key
    CZGUSIXMZVURDU-JZXHSEFVSA-N
    2.1.4 Canonical SMILES
    CCC(C)C(C(=O)NC(CC1=CN=CN1)C(=O)N2CCCC2C(=O)NC(CC3=CC=CC=C3)C(=O)O)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(C(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC(=O)O)N
    2.1.5 Isomeric SMILES
    CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)O)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)O)N
    2.2 Synonyms
    2.2.1 MeSH Synonyms

    1. 5 L Isoleucine Angiotensin Ii

    2. 5-l-isoleucine Angiotensin Ii

    3. Ang-(1-8)octapeptide

    4. Angiotensin Ii, 5-l-isoleucine

    5. Angiotensin Ii, Ile(5)-

    6. Angiotensin Ii, Isoleucine(5)-

    7. Angiotensin Ii, Val(5)-

    8. Angiotensin Ii, Valine(5)-

    9. Angiotensin-(1-8) Octapeptide

    10. Isoleucine(5)-angiotensin

    11. Isoleucyl(5)-angiotensin Ii

    12. Valyl(5)-angiotensin Ii

    2.2.2 Depositor-Supplied Synonyms

    1. 4474-91-3

    2. Angiotensin Ii Human

    3. Hypertensin

    4. Human Angiotensin Ii

    5. Angiotensin Ii (human)

    6. Ang Ii

    7. Giapreza

    8. 5-l-isoleucineangiotensin Ii

    9. Angiotensin Ii (mouse)

    10. 5-isoleucine-angiotensin Ii

    11. Asp-arg-val-tyr-ile-his-pro-phe

    12. Drvyihpf

    13. 1-8-angiotensin I

    14. Angiotensin Ii, Human

    15. Ile(5)-angiotensin Ii

    16. Isoleucine5-angiotensin Ii

    17. Chebi:2719

    18. Ang-(1-8)octapeptide

    19. Isoleucine(5)-angiotensin Ii

    20. Chembl408403

    21. 1-l-aspasaginyl-5-l-valyl Angiotensin Octapeptide

    22. 11128-99-7

    23. Delivert

    24. Angiotensin Ii (usan)

    25. L-alpha-aspartyl-l-arginyl-l-valyl-l-tyrosyl-l-isoleucyl-l-histidyl-l-prolyl-l-phenylalanine

    26. (2s,5s,8s,11s,14s,17s)-2-((1h-imidazol-5-yl)methyl)-17-amino-5-((s)-sec-butyl)-1-((s)-2-(((s)-1-carboxy-2-phenylethyl)carbamoyl)pyrrolidin-1-yl)-14-(3-((diaminomethylene)amino)propyl)-8-(4-hydroxybenzyl)-11-isopropyl-1,4,7,10,13,16-hexaoxo-3,6,9,12,15-pentaazanonadecan-19-oic Acid

    27. N-(1-(n-(n-(n-(n-(n(2)-l-alpha-aspartyl-l-arginyl)-l-valyl)-l-tyrosyl)-l-isoleucyl)-l-histidyl)-l-prolyl)-l-phenylalanine

    28. Angiotensinii,human

    29. Ile5-angiotensin Ii

    30. Angiotensin Ii, Ile(5)-

    31. Angiotensin Ii [inn:jan]

    32. Unii-m089efu921

    33. Hypertensin Ii

    34. Angiotensin 2

    35. Angiotensin Ii, 5-l-isoleucine-

    36. Delivert (tn)

    37. C50h71n13o12

    38. Angiotensin Ii Heavy

    39. Angiotensin Ii (rat)

    40. Angiotensin Ii (9ci)

    41. Angiotensin Ii-human

    42. Angiotensin Ii Acetate Salt

    43. Schembl1189

    44. Angiotensin Ii (human Type)

    45. Gtpl2504

    46. Ljpc-501

    47. Schembl9013957

    48. Schembl20502357

    49. Dtxsid30196288

    50. Chebi:131170

    51. Ty-10721

    52. M089efu921

    53. Angiotensin Ii (human Type) (jan)

    54. Bdbm50228195

    55. Bdbm50236697

    56. Akos016010178

    57. Zinc169676920

    58. Db11842

    59. H-asp-arg-val-tyr-ile-his-pro-phe-oh

    60. Ncgc00167130-01

    61. Hy-13948

    62. L-phenylalanine, N-(1-(n-(n-(n-(n-(n2-l-alpha-aspartyl-l-arginyl)-l-valyl)-l-tyrosyl)-l-isoleucyl)-l-histidyl)-l-prolyl)-

    63. Asp1-arg2-val3-tyr4-ile5-his6-pro7-phe8

    64. C02135

    65. C75211

    66. D02014

    67. Drvy-i*-hpf [i*= I(13c6,15n)]

    68. A872469

    69. Q412999

    70. Ang-(1-8)octapeptide, Hypertensin, 4474-91-3, Giapreza

    71. Conalbumin (328-332), 1226776-54-0, Rvpsl Peptide

    72. Proteomass(tm) Angiotensin Ii Maldi-ms Standard, Vial Of 10 Nmol

    73. (3s)-3-amino-3-{[(1s)-1-{[(1s)-1-{[(1s)-1-{[(1s,2s)-1-{[(2s)-1-[(2s)-2-{[(1s)-1-carboxy-2-phenylethyl]carbamoyl}pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]carbamoyl}-2-methylbutyl]carbamoyl}-2-(4-hydroxyphenyl)ethyl]carbamoyl}-2-methylpropyl]carbamoyl}-4-[(diaminomethylidene)amino]butyl]carbamoyl}propanoic Acid

    74. Alanine, N-(1-(n-(n-(n-(n-(n2-l-alpha-aspartyl-l-arginyl)-l-valyl)-l-tyrosyl)-l-isoleucyl)-l-histidyl)-l-prolyl)-3-phenyl-, L-

    75. L-phenylalanine, L-alpha-aspartyl-l-arginyl-l-valyl-l-tyrosyl-l-isoleucyl-l-histidyl-l-prolyl-

    2.3 Create Date
    2005-06-01
    3 Chemical and Physical Properties
    Molecular Weight 1046.2 g/mol
    Molecular Formula C50H71N13O12
    XLogP3-1.7
    Hydrogen Bond Donor Count13
    Hydrogen Bond Acceptor Count15
    Rotatable Bond Count29
    Exact Mass1045.53451475 g/mol
    Monoisotopic Mass1045.53451475 g/mol
    Topological Polar Surface Area409 Ų
    Heavy Atom Count75
    Formal Charge0
    Complexity1980
    Isotope Atom Count0
    Defined Atom Stereocenter Count9
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Angiotensin II is a vasoconstrictor indicated for increasing blood pressure in adults with septic or other distributive shock.

    FDA Label

    Giapreza is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies.

    5 Pharmacology and Biochemistry
    5.1 Pharmacology

    Angiotensin II is a naturally occurring peptide hormone of the renin-angiotensin-aldosterone-system (RAAS) that has the capacity to cause vasoconstriction and an increase in blood pressure in the human body. In the RAAS, juxtaglomerular cells of the renal afferent arteriole synthesize the proteolytic enzyme renin. Although stored in an inactive form called pro-renin, decreases in arterial blood pressure or extracellular fluid volume depletion can cause various enzymatic reactions to release active renin into the systemic circulation and surrounding tissues. Such renin release allows for the production of the alpha-2-globulin angiotensinogen predominantly in the liver and to some extent, the kidneys and other organs. Angiotensin I, itself a decapeptide with weak biological activity, is produced from angiotensinogen and then quickly converted to angiotensin II by angiotensin converting enzymes (ACE). Consequently, angiotensin II demonstrates its strong vasopressor activity when it is rapidly degraded by aminopeptidases A and M into further entities like angiotensin III and angiotensin IV, respectively. Such species like angiotensin III can then bind and interact with specific G protein coupled receptors like angiotensin receptor 1, or AT-1 where strong vasoconstricson can occur. Furthermore, in the ATHOS-3 clinical trial, for the 114 (70%) patient subjects in the angiotensin II arm who reached the target mean arterial pressure (MAP) at Hour 3, the median time to reach the target MAP endpoint was approximately 5 minutes. The angiotensin II was titrated to effect for each individual patient..

    5.2 MeSH Pharmacological Classification

    Vasoconstrictor Agents

    Drugs used to cause constriction of the blood vessels. (See all compounds classified as Vasoconstrictor Agents.)

    5.3 FDA Pharmacological Classification
    5.3.1 Pharmacological Classes
    Vasoconstrictor [EPC]; Vasoconstriction [PE]
    5.4 ATC Code

    C09

    C - Cardiovascular system

    C01 - Cardiac therapy

    C01C - Cardiac stimulants excl. cardiac glycosides

    C01CX - Other cardiac stimulants

    C01CX09 - Angiotensin II

    5.5 Absorption, Distribution and Excretion

    Absorption

    Following the intravenous infusion of angiotensin II in adult patients with septic or other distributive shock, the serum levels of angiotensin II observed were similar at baseline and hour 3 after the intravenous infusion. After 3 hours of treatment, the serum level of angiotensin I (the angiotensin II precursos peptide) is however, reduced by about 40%.

    Route of Elimination

    The official prescribing information notes that no specific studies have been conducted that examine the elimination of angiotensin II.

    Volume of Distribution

    The official prescribing information for angiotensin II notes that no specific studies have yet been conducted that examine the distribution of angiotensin II.

    Clearance

    The official prescribing information notes that the clearnace of angiotensin II is not dependent on hepatic function or renal function.

    5.6 Metabolism/Metabolites

    It is metabolized by aminopeptidase A and angiotensin converting enzyme 2 to angiotensin-(2-8) [angiotensin III] and angiotensin-(1-7), respectively in plasma, erythrocytes and many of the major organs (i.e. intestine, kidney, liver and lung). Angiotensin II type 1 receptor (AT1) mediated activity of angiotensin III is approximately 40% of angiotensin II; however, aldosterone synthesis activity is similar to angiotensin II. Angiotensin-(1-7) exerts the opposite effects of angiotensin II on AT1 receptors and causes vasodilation. Nevertheless, the official prescribing information also notes that no formal studies have been conducted that examine the metabolism of angiotensin II.

    5.7 Biological Half-Life

    The plasma half-life of intravenously administered angiotensin II is less than one minute.

    5.8 Mechanism of Action

    As part of the renin-angiotensin-aldosterone-system (RAAS), angiotensin II raises blood pressure by vasoconstriction, increased aldosterone release by the adrenal zona glomerulosa, sodium and water reabsorption in the proximal tubular cells, and vasopressin secretion The direct action of angiotensin II on surrounding vessel walls is facilitated by binding to the G-protein-coupled angiotensin II receptor type 1 (AT-1) on vascular smooth muscle cells, which stimulates Ca2+/calmodulin-dependent phosphorylation of myosin and causes smooth muscle contraction that results in vasoconstriction. The RAAS is ultimately regulated by a negative feedback effect of angiotensin II on renin production by the juxtaglomerular cells of the renal afferent arteriole. Unresuscitated septic shock associated with marked hypovolemia, extracellular fluid volume depletion, decreased cardiac output, low arterial blood pressure and decreased systemic vascular resistance causes an increase in renin secretion by the juxtaglomerular cells, resulting in elevated angiotensin II plasma levels and an increased secretion of aldosterone from the adrenal cortex. Angiotensin II binding to AT-1 receptors causes dose-dependent vasoconstriction of both afferent and efferent glomerular arterioles. The most pronounced effect of angiotensin II results on efferent arterioles, resulting in reduced renal blood flow and increased glomerular filtration pressure.

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Granulation

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Patents & EXCLUSIVITIES

    Check the patents & exclusivity for this product

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ANALYTICAL

    Upload your methods for free, ask us

    Analytical Methods

    read-more
    read-more

    ABOUT THIS PAGE

    Angiotensin II Manufacturers

    A Angiotensin II manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Angiotensin II, including repackagers and relabelers. The FDA regulates Angiotensin II manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Angiotensin II API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Angiotensin II manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    Angiotensin II Suppliers

    A Angiotensin II supplier is an individual or a company that provides Angiotensin II active pharmaceutical ingredient (API) or Angiotensin II finished formulations upon request. The Angiotensin II suppliers may include Angiotensin II API manufacturers, exporters, distributors and traders.

    click here to find a list of Angiotensin II suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    Angiotensin II USDMF

    A Angiotensin II DMF (Drug Master File) is a document detailing the whole manufacturing process of Angiotensin II active pharmaceutical ingredient (API) in detail. Different forms of Angiotensin II DMFs exist exist since differing nations have different regulations, such as Angiotensin II USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Angiotensin II DMF submitted to regulatory agencies in the US is known as a USDMF. Angiotensin II USDMF includes data on Angiotensin II's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Angiotensin II USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Angiotensin II suppliers with USDMF on PharmaCompass.

    Angiotensin II NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Angiotensin II as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Angiotensin II API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Angiotensin II as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Angiotensin II and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Angiotensin II NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Angiotensin II suppliers with NDC on PharmaCompass.

    Angiotensin II GMP

    Angiotensin II Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Angiotensin II GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Angiotensin II GMP manufacturer or Angiotensin II GMP API supplier for your needs.

    Angiotensin II CoA

    A Angiotensin II CoA (Certificate of Analysis) is a formal document that attests to Angiotensin II's compliance with Angiotensin II specifications and serves as a tool for batch-level quality control.

    Angiotensin II CoA mostly includes findings from lab analyses of a specific batch. For each Angiotensin II CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Angiotensin II may be tested according to a variety of international standards, such as European Pharmacopoeia (Angiotensin II EP), Angiotensin II JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Angiotensin II USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search